Atomwise
Atomwise, based in San Francisco, CA, leverages artificial intelligence to revolutionize drug discovery, focusing on small-molecule drug candidates in immunology and oncology.
Services
Atomwise uses artificial intelligence to transform drug discovery, aiming to create better medicines. Their primary service involves leveraging a machine learning-based discovery engine that combines convolutional neural networks with vast chemical libraries. They focus on solving the hardest problems in drug discovery to find innovative medicines for tomorrow. Atomwise also offers out-licensing for their developed assets, providing opportunities for partners to utilize their AI discoveries.
Industry
Atomwise operates within the healthcare industry, specifically focusing on drug discovery and delivery. Their innovative approach involves using artificial intelligence to streamline the discovery and development of small-molecule drug candidates. They contribute to the healthcare sector with their machine learning-driven techniques aimed at tackling complex problems in drug discovery.
AI-Enabled Drug Discovery
Atomwise is pioneering the use of artificial intelligence in drug discovery. They have developed a discovery engine powered by convolutional neural networks and large chemical libraries to identify potential drug candidates. This AI-enabled approach has led to advancements in their proprietary pipeline, which includes small-molecule drug candidates in fields such as immunology and oncology, targeting proteins like TYK2 and RIPK2.
Historical Background
Founded as part of Y Combinator's W15 batch, Atomwise has been recognized as one of Y Combinator's top companies. Since its inception, the company has focused on applying deep learning to structure-based drug design. Their innovative methods have garnered attention from various publications and news outlets, solidifying their position as a leader in AI-driven drug discovery.
Key Projects and Pipeline
Atomwise is advancing a robust pipeline of small-molecule drug candidates primarily in the areas of immunology and oncology. Key targets within their pipeline include TYK2 and RIPK2. The company is actively engaged in both wholly owned and co-developed projects, showcasing their commitment to developing effective treatments through innovative AI methodologies. Additionally, they offer out-licensing options for their various assets, extending their impact within the pharmaceutical industry.